Trial Profile
The research for the adherence and QOL for oral anti-coagulants(OAC) in patients with atrial fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Mar 2015
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Thrombosis
- Focus Therapeutic Use
- Sponsors Bayer Yakuhin
- 13 Mar 2015 Status changed from recruiting to completed as per University Hospital Medical Information Network record.
- 24 Jan 2014 New trial record